Analysts expect AxoGen, Inc Common Stock (NASDAQ:AXGN) to post earnings of ($0.05) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for AxoGen, Inc Common Stock’s earnings. AxoGen, Inc Common Stock reported earnings per share of ($0.06) in the same quarter last year, which indicates a positive year-over-year growth rate of 16.7%. The business is expected to report its next earnings report on Wednesday, August 1st.

According to Zacks, analysts expect that AxoGen, Inc Common Stock will report full-year earnings of ($0.13) per share for the current fiscal year. For the next fiscal year, analysts expect that the business will report earnings of ($0.01) per share. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow AxoGen, Inc Common Stock.

AxoGen, Inc Common Stock (NASDAQ:AXGN) last issued its quarterly earnings data on Monday, April 30th. The medical equipment provider reported ($0.11) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.11). AxoGen, Inc Common Stock had a negative net margin of 18.83% and a negative return on equity of 61.66%. The business had revenue of $17.30 million during the quarter, compared to analysts’ expectations of $17.16 million. AxoGen, Inc Common Stock’s revenue was up 41.8% compared to the same quarter last year.

A number of analysts have recently weighed in on AXGN shares. Jefferies Financial Group boosted their price objective on shares of AxoGen, Inc Common Stock to $45.00 and gave the stock a “buy” rating in a research note on Monday, March 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective (up from $37.00) on shares of AxoGen, Inc Common Stock in a research note on Tuesday, May 1st. JMP Securities boosted their price objective on shares of AxoGen, Inc Common Stock from $34.00 to $43.00 and gave the stock a “market outperform” rating in a research note on Tuesday, May 1st. ValuEngine upgraded shares of AxoGen, Inc Common Stock from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, Leerink Swann reiterated an “outperform” rating and set a $70.00 target price on shares of AxoGen, Inc Common Stock in a research note on Tuesday, June 26th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $41.29.

Shares of AxoGen, Inc Common Stock traded down $0.53, reaching $51.80, on Wednesday, Marketbeat.com reports. The stock had a trading volume of 357,472 shares, compared to its average volume of 382,472. The company has a current ratio of 3.32, a quick ratio of 2.81 and a debt-to-equity ratio of 0.82. AxoGen, Inc Common Stock has a fifty-two week low of $14.30 and a fifty-two week high of $55.55. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -167.10 and a beta of 0.04.

In related news, SVP Shawn F. Mccarrey sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $43.47, for a total transaction of $434,700.00. Following the completion of the transaction, the senior vice president now directly owns 33,057 shares in the company, valued at approximately $1,436,987.79. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 7.86% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in AXGN. Ladenburg Thalmann Financial Services Inc. raised its stake in AxoGen, Inc Common Stock by 41.6% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,575 shares of the medical equipment provider’s stock valued at $167,000 after purchasing an additional 1,345 shares during the last quarter. Princeton Capital Management LLC acquired a new position in AxoGen, Inc Common Stock during the 1st quarter valued at $183,000. Paloma Partners Management Co acquired a new position in AxoGen, Inc Common Stock during the 4th quarter valued at $215,000. Brown Advisory Inc. acquired a new position in AxoGen, Inc Common Stock during the 1st quarter valued at $215,000. Finally, Guggenheim Capital LLC acquired a new position in AxoGen, Inc Common Stock during the 4th quarter valued at $228,000. Hedge funds and other institutional investors own 75.92% of the company’s stock.

AxoGen, Inc Common Stock Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Get a free copy of the Zacks research report on AxoGen, Inc Common Stock (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen, Inc Common Stock (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.